Terms: = Prostate cancer AND OMD, osteoadherin, 4958, ENSG00000127083, Q99983, SLRR2C
17 results:
1. Stereotactic ablative radiation therapy in metastatic prostate cancer.
Bazyar S; Mannuel H; Tran PT
Curr Opin Oncol; 2024 May; 36(3):180-185. PubMed ID: 38362949
[TBL] [Abstract] [Full Text] [Related]
2. Comparison of Health-Related Quality of Life Changes in prostate cancer Patients Undergoing Laparoscopic versus Robotic-Assisted Laparoscopic Radical prostatectomy: A Systematic review.
Yazici S; Tonyali S
Urol J; 2024 Feb; 21(1):14-19. PubMed ID: 37727913
[TBL] [Abstract] [Full Text] [Related]
3. Unravelling oligometastatic disease from the perspective of radiation and medical oncology. Part I: non-small cell lung cancer and breast cancer.
Rodríguez Pérez A; Felip Font E; Chicas-Sett R; Montero-Luis Á; de Paz Arias L; González-Del-Alba A; López-Campos F; López López C; Hernando Requejo O; Conde-Moreno AJ; Arranz Arija JÁ; de Castro Carpeño J
Clin Transl Oncol; 2023 Apr; 25(4):882-896. PubMed ID: 36525231
[TBL] [Abstract] [Full Text] [Related]
4. Unravelling oligometastatic disease from the perspective of radiation and medical oncology. Part II: prostate cancer and colorectal cancer.
Conde-Moreno AJ; González-Del-Alba A; López-Campos F; López López C; Requejo OH; de Castro Carpeño J; Chicas-Sett R; de Paz Arias L; Montero-Luis Á; Pérez AR; Font EF; Arija JÁA
Clin Transl Oncol; 2023 Apr; 25(4):897-911. PubMed ID: 36525230
[TBL] [Abstract] [Full Text] [Related]
5. Review of Prospective Trials Assessing the Role of Stereotactic Body Radiation Therapy for Metastasis-directed Treatment in Oligometastatic Genitourinary cancers.
Huynh MA; Tang C; Siva S; Berlin A; Hannan R; Warner A; Koontz B; De Meeleer G; Palma D; Ost P; Tran PT
Eur Urol Oncol; 2023 Feb; 6(1):28-38. PubMed ID: 36283936
[TBL] [Abstract] [Full Text] [Related]
6. Patient and Treatment Factors Associated With Improved Local Control and Survival in Oligometastatic Bone Disease: Results From a Large Single-Institution Experience Using Stereotactic Body Radiation Therapy.
Thomas MC; Chen YH; Fite E; Pangilinan A; Bubelo K; Spektor A; Balboni TA; Huynh MA
Int J Radiat Oncol Biol Phys; 2022 Nov; 114(4):747-761. PubMed ID: 35840113
[TBL] [Abstract] [Full Text] [Related]
7. Completeness of Reporting Oligometastatic Disease Characteristics in the Literature and Influence on Oligometastatic Disease Classification Using the ESTRO/EORTC Nomenclature.
Nevens D; Jongen A; Kindts I; Billiet C; Deseyne P; Joye I; Lievens Y; Guckenberger M
Int J Radiat Oncol Biol Phys; 2022 Nov; 114(4):587-595. PubMed ID: 35738308
[TBL] [Abstract] [Full Text] [Related]
8. A Systematic Review of the Cost-Effectiveness of Stereotactic Radiation Therapy for cancer Oligometastases.
Verma V; Yegya-Raman N; Sprave T; Han G; Kantarjian HM; Welsh JW; Chang JY; Lin SH
Int J Radiat Oncol Biol Phys; 2022 Dec; 114(5):977-988. PubMed ID: 35675852
[TBL] [Abstract] [Full Text] [Related]
9. Metastasis-directed Therapy in prostate cancer: Prognostic Significance of the ESTRO/EORTC Classification in Oligometastatic Bone Disease.
Nicholls L; Chapman E; Khoo V; Suh YE; Tunariu N; Wang Y; van As N
Clin Oncol (R Coll Radiol); 2022 Jan; 34(1):63-69. PubMed ID: 34756755
[TBL] [Abstract] [Full Text] [Related]
10. Late metastatic presentation is associated with improved survival and delayed wide-spread progression after ablative stereotactic body radiotherapy for oligometastasis.
Chen X; Chen H; Poon I; Erler D; Badellino S; Biswas T; Dagan R; Foote M; Louie AV; Ricardi U; Sahgal A; Redmond KJ
Cancer Med; 2021 Sep; 10(18):6189-6198. PubMed ID: 34432390
[TBL] [Abstract] [Full Text] [Related]
11. Comparison of MRI, PET, and 18F-choline PET/MRI in patients with oligometastatic recurrent prostate cancer.
Evangelista L; Cassarino G; Lauro A; Morlacco A; Sepulcri M; Nguyen AAL; Ietto F; Cecchin D; Lacognata C; Zucchetta P
Abdom Radiol (NY); 2021 Sep; 46(9):4401-4409. PubMed ID: 34047801
[TBL] [Abstract] [Full Text] [Related]
12. Comparative study of surgical orchidectomy and medical castration in treatment efficacy, adverse effects and cost based on a large prospective metastatic prostate cancer registry.
Tan YG; Poon RJ; Pang LJ; Villanueva A; Huang HH; Chen K; Ng TK; Tay KJ; Ho HS; Yuen JS
Urol Oncol; 2020 Aug; 38(8):682.e1-682.e9. PubMed ID: 32475745
[TBL] [Abstract] [Full Text] [Related]
13. A risk-based approach to identifying oligometastatic disease on imaging.
deSouza NM; Tempany CM
Int J Cancer; 2019 Feb; 144(3):422-430. PubMed ID: 30098215
[TBL] [Abstract] [Full Text] [Related]
14. Oligometastatic recurrent prostate cancer detects by fluorine-18-choline positron emission tomography/computed tomography in patients with prostate-specific antigen levels of up to 5 ng/ml.
Evangelista L; Cuppari L; Guttilla A; Gardi M; Agostini A; Ruggera L; Basso U; Saladini G
Nucl Med Commun; 2018 Mar; 39(3):260-267. PubMed ID: 29381584
[TBL] [Abstract] [Full Text] [Related]
15. Strategies and technical challenges for imaging oligometastatic disease: Recommendations from the European Organisation for Research and Treatment of cancer imaging group.
deSouza NM; Liu Y; Chiti A; Oprea-Lager D; Gebhart G; Van Beers BE; Herrmann K; Lecouvet FE
Eur J Cancer; 2018 Mar; 91():153-163. PubMed ID: 29331524
[TBL] [Abstract] [Full Text] [Related]
16. Study on the distribution features of bone metastases in prostate cancer.
Wang C; Shen Y
Nucl Med Commun; 2012 Apr; 33(4):379-83. PubMed ID: 22293499
[TBL] [Abstract] [Full Text] [Related]
17. Common malignancy-associated regions of transcriptional activation (MARTA) in human prostate, breast, ovarian, and colon cancers are targets for DNA amplification.
Glinsky GV; Ivanova YA; Glinskii AB
Cancer Lett; 2003 Nov; 201(1):67-77. PubMed ID: 14580688
[TBL] [Abstract] [Full Text] [Related]